Hematopoietic Cell Transplantation for Aplastic Anemia

Georges, George E.; Storb, Rainer

doi:10.1002/9781118416426.ch46

Cited by 4 publications

(3 citation statements)

References 181 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Bone marrow is the only acceptable HSC source for patients with SAA. Additional details regarding the optimal conditioning regimen, cell dose and post-transplant immunosuppression were recently reviewed(31). …”

Section: Hla-identical Sibling Donor Bmtmentioning

confidence: 99%

Hematopoietic stem cell transplantation for acquired aplastic anemia

Georges

Storb²

2016

Current Opinion in Hematology

Self Cite

View full text Add to dashboard Cite

Purpose of review There has been steady improvement in outcomes with allogeneic bone marrow transplantation (BMT) for severe aplastic anemia (SAA), due to progress in optimization of the conditioning regimens, donor hematopoietic cell source and supportive care. Here we review recently published data that highlight the improvements and current issues in the treatment of SAA. Recent findings Approximately one-third of AA patients treated with immune suppression therapy (IST) have acquired mutations in myeloid cancer candidate genes. Because of the greater probability for eventual failure of IST, human leukocyte antigen (HLA)-matched sibling donor BMT is the first-line of treatment for SAA. HLA-matched unrelated donor (URD) BMT is generally recommended for patients who have failed IST. However, in younger patients for whom a 10/10-HLA-allele matched URD can be rapidly identified, there is a strong rationale to proceed with URD BMT as first-line therapy. HLA-haploidentical BMT using post-transplant cyclophosphamide (PT-CY) conditioning regimens, is now a reasonable second-line treatment for patients who failed IST. Summary Improved outcomes have led to an increased first-line role of BMT for treatment of SAA. The optimal cell source from an HLA-matched donor is bone marrow. Additional studies are needed to determine the optimal conditioning regimen for HLA-haploidentical donors.

show abstract

Section: Hla-identical Sibling Donor Bmtmentioning

confidence: 99%

Hematopoietic stem cell transplantation for acquired aplastic anemia

Georges

Storb²

2016

Current Opinion in Hematology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Effective treatment for severe aplastic anemia (SAA) is either allogeneic bone marrow transplantation (BMT) [1,2] or nontransplant immunosuppressive therapy (IST) containing antithymocyte globulin (ATG) [3,4]. Both treatment approaches have advanced over the recent decades to achieve significantly improved outcomes.…”

mentioning

confidence: 99%

Consider Allogeneic Bone Marrow Transplantation for Older, FitPatients with Aplastic Anemia

Georges

2019

Biology of Blood and Marrow Transplantation

Self Cite

View full text Add to dashboard Cite

“…Portanto, este estudo incluiu 66 pacientes dos dois centros de TMO.de plaquetas ≥20 x 10 9 /L. O regime de condicionamento foi classificado como mieloablativo ou não mieloblativo64 . Nos pacientes transplantados, a falha de enxertia primária foi caracterizada como contagem de neutrófilos abaixo de 500/uL após o D+2898 .…”

unclassified

Comprimento telomérico dos leucócitos do sangue periférico de doadores e receptores de transplante de medula óssea para anemia aplástica grave: associação com resultados clínicos após o transplante

Dias¹

View full text Add to dashboard Cite

show abstract

Hematopoietic Cell Transplantation for Aplastic Anemia

Cited by 4 publications

References 181 publications

Hematopoietic stem cell transplantation for acquired aplastic anemia

Hematopoietic stem cell transplantation for acquired aplastic anemia

Consider Allogeneic Bone Marrow Transplantation for Older, FitPatients with Aplastic Anemia

Comprimento telomérico dos leucócitos do sangue periférico de doadores e receptores de transplante de medula óssea para anemia aplástica grave: associação com resultados clínicos após o transplante

Contact Info

Product

Resources

About